GRPHライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (22 3月 2024 @ 05:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
本日の出来高	299 406
平均出来高	40 955.00
時価総額	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

ボリューム相関

長: 0.15 (neutral)

短: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. 相関

10 最も正の相関
SGLB	0.895
MTEX	0.893
ZENV	0.882
GRIN	0.88
PIII	0.874
RIVN	0.872
LCAP	0.868
SOPA	0.868
LAWS	0.865
OP	0.865

10 最も負の相関
DYNT	-0.95
FTFT	-0.949
DGLY	-0.935
ATNX	-0.924
CRNC	-0.921
CFRX	-0.918
FGEN	-0.914
IPHA	-0.913
CSWI	-0.912
ECOR	-0.912

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Graphite Bio, Inc. 相関 - 通貨/商品

-0.53
( weak negative )

-0.46
( neutral )

0.00
( neutral )

-0.22
( neutral )

0.20
( neutral )

0.27
( neutral )

Graphite Bio, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2023
収益:	$0
総利益:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2022
収益:	$0
総利益:	$-8.35M (0.00 %)
EPS:	$-1.760

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.